{"id":"NCT00397631","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Initial Combination With Pioglitazone Study (0431-064)","officialTitle":"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12-19","primaryCompletion":"2008-06-28","completion":"2008-06-28","firstPosted":"2006-11-09","resultsPosted":"2009-07-10","lastUpdate":"2017-05-12"},"enrollment":520,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"sitagliptin 100 mg q.d./pioglitazone 30 mg q.d","otherNames":[]},{"type":"DRUG","name":"Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"A clinical study to evaluate the safety and efficacy of the initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus not on treatment with insulin or oral antihyperglycemic therapy.","primaryOutcome":{"measure":"Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24","timeFrame":"Baseline and 24 weeks","effectByArm":[{"arm":"Sitagliptin 100 mg q.d. + Pioglitazone 30 mg q.d.","deltaMin":-2.38,"sd":null},{"arm":"Pioglitazone 30 mg q.d.","deltaMin":-1.49,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21235696","22405352"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8},"commonTop":["Any Infections and infestations","Nasopharyngitis","Any Nervous system disorders","Headache"]}}